BRAF and colorectal cancer: However, in spite of the molecular similarities between melanoma and colorectal cancers, BRAF inhibitors have experienced opposite results with improved survival in patients with melanoma [19] and significant resistance in colorectal cancers [20], suggesting drastic mechanistic differences.